BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 11562285)

  • 1. Vitamin D analogs: mechanism of action and therapeutic applications.
    Nagpal S; Lu J; Boehm MF
    Curr Med Chem; 2001 Nov; 8(13):1661-79. PubMed ID: 11562285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D receptor as a drug discovery target.
    Pinette KV; Yee YK; Amegadzie BY; Nagpal S
    Mini Rev Med Chem; 2003 May; 3(3):193-204. PubMed ID: 12570835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noncalcemic actions of vitamin D receptor ligands.
    Nagpal S; Na S; Rathnachalam R
    Endocr Rev; 2005 Aug; 26(5):662-87. PubMed ID: 15798098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators.
    Ma Y; Khalifa B; Yee YK; Lu J; Memezawa A; Savkur RS; Yamamoto Y; Chintalacharuvu SR; Yamaoka K; Stayrook KR; Bramlett KS; Zeng QQ; Chandrasekhar S; Yu XP; Linebarger JH; Iturria SJ; Burris TP; Kato S; Chin WW; Nagpal S
    J Clin Invest; 2006 Apr; 116(4):892-904. PubMed ID: 16528410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D receptor modulators for inflammation and cancer.
    Yee YK; Chintalacharuvu SR; Lu J; Nagpal S
    Mini Rev Med Chem; 2005 Aug; 5(8):761-78. PubMed ID: 16101412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of two novel 14-epivitamin D3 analogs with vitamin D3 receptor-retinoid X receptor heterodimers on vitamin D3 responsive elements.
    Verlinden L; Verstuyf A; Quack M; Van Camp M; Van Etten E; De Clercq P; Vandewalle M; Carlberg C; Bouillon R
    J Bone Miner Res; 2001 Apr; 16(4):625-38. PubMed ID: 11315990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular evaluation of vitamin D3 receptor agonists designed for topical treatment of skin diseases.
    Bury Y; Ruf D; Hansen CM; Kissmeyer AM; Binderup L; Carlberg C
    J Invest Dermatol; 2001 May; 116(5):785-92. PubMed ID: 11348471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D receptor ligands for osteoporosis.
    Cheskis BJ; Freedman LP; Nagpal S
    Curr Opin Investig Drugs; 2006 Oct; 7(10):906-11. PubMed ID: 17086935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D analogs as therapeutic agents: a clinical study update.
    Wu-Wong JR; Tian J; Goltzman D
    Curr Opin Investig Drugs; 2004 Mar; 5(3):320-6. PubMed ID: 15083599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noncalcemic actions of 1,25-dihydroxyvitamin D3 and clinical applications.
    Holick MF
    Bone; 1995 Aug; 17(2 Suppl):107S-111S. PubMed ID: 8579891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of stereochemistry on the actions of vitamin D.
    Chiellini G; DeLuca HF
    Curr Top Med Chem; 2011; 11(7):840-59. PubMed ID: 21291397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance of HBL100 human breast epithelial cells to vitamin D action.
    Agadir A; Lazzaro G; Zheng Y; Zhang XK; Mehta R
    Carcinogenesis; 1999 Apr; 20(4):577-82. PubMed ID: 10223184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of vitamin D analog-induced heterodimerization of vitamin D receptor with retinoid X receptor using the yeast two-hybrid system.
    Zhao XY; Eccleshall TR; Krishnan AV; Gross C; Feldman D
    Mol Endocrinol; 1997 Mar; 11(3):366-78. PubMed ID: 9058382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salt concentration determines 1,25-dihydroxyvitamin D3 dependency of vitamin D receptor-retinoid X receptor--vitamin D-responsive element complex formation.
    Kimmel-Jehan C; Jehan F; DeLuca HF
    Arch Biochem Biophys; 1997 May; 341(1):75-80. PubMed ID: 9143355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel 1alpha,25-dihydroxyvitamin D3 analogues with the side chain at C12.
    González-Avión XC; Mouriño A; Rochel N; Moras D
    J Med Chem; 2006 Mar; 49(5):1509-16. PubMed ID: 16509569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3.
    Boehm MF; Fitzgerald P; Zou A; Elgort MG; Bischoff ED; Mere L; Mais DE; Bissonnette RP; Heyman RA; Nadzan AM; Reichman M; Allegretto EA
    Chem Biol; 1999 May; 6(5):265-75. PubMed ID: 10322128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic applications for novel non-hypercalcemic vitamin D receptor ligands.
    Choi M; Makishima M
    Expert Opin Ther Pat; 2009 May; 19(5):593-606. PubMed ID: 19441936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D3-retinoid X receptor dimerization, DNA binding, and transactivation are differentially affected by analogs of 1,25-dihydroxyvitamin D3.
    Cheskis B; Lemon BD; Uskokovic M; Lomedico PT; Freedman LP
    Mol Endocrinol; 1995 Dec; 9(12):1814-24. PubMed ID: 8614417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinoid X receptor-specific ligands synergistically upregulate 1, 25-dihydroxyvitamin D3-dependent transcription in epidermal keratinocytes in vitro and in vivo.
    Li XY; Xiao JH; Feng X; Qin L; Voorhees JJ
    J Invest Dermatol; 1997 Apr; 108(4):506-12. PubMed ID: 9077482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D receptor agonists: opportunities and challenges in drug discovery.
    Takahashi T; Morikawa K
    Curr Top Med Chem; 2006; 6(12):1303-16. PubMed ID: 16848744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.